Sensei Biotherapeutics Inc (SNSE) - Total Assets
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) holds total assets worth $205.38 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sensei Biotherapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Sensei Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see how much is Sensei Biotherapeutics Inc worth for the company's overall valuation and market capitalisation.
Sensei Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Sensei Biotherapeutics Inc's total assets of $205.38 Million consist of 93.9% current assets and 6.1% non-current assets. Review Sensei Biotherapeutics Inc (SNSE) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Sensei Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Sensei Biotherapeutics Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sensei Biotherapeutics Inc's current assets represent 93.9% of total assets in 2025, an increase from 69.2% in 2018.
- Cash Position: Cash and equivalents constituted 37.9% of total assets in 2025, up from 35.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Sensei Biotherapeutics Inc Competitors by Total Assets
Key competitors of Sensei Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Sensei Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.39 | 6.82 | 42.22 |
| Quick Ratio | 14.39 | 6.82 | 42.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $190.04 Million | $30.45 Million | $161.69 Million |
Sensei Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sensei Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | -49.5% |
| Total Assets | $22.90 Million |
| Market Capitalization | $18.59 Million USD |
Valuation Analysis
Near Book Valuation: The market values Sensei Biotherapeutics Inc's assets close to their book value (0.81x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Sensei Biotherapeutics Inc's assets decreased by 49.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sensei Biotherapeutics Inc (2018–2025)
The table below shows the annual total assets of Sensei Biotherapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $22.90 Million | -49.51% |
| 2024-12-31 | $45.36 Million | -39.01% |
| 2023-12-31 | $74.37 Million | -37.17% |
| 2022-12-31 | $118.38 Million | -22.74% |
| 2021-12-31 | $153.22 Million | +615.07% |
| 2020-12-31 | $21.43 Million | +1660.72% |
| 2019-12-31 | $1.22 Million | -34.22% |
| 2018-12-31 | $1.85 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more